This document describes new features, noteworthy changes, and provides guidance on upgrading from earlier versions. If you see anything missing or inaccurate, please submit a pull-request against ...

The free version limits you to 10 active and editable documents, which isn’t a big deal if 3D design is something you do only occasionally, but it could be restrictive for more frequent users. Finally ...

A man is on trial accused of repeatedly drugging and raping his wife, as well as encouraging dozens of other men to rape her in their home while she was unconscious, court documents show. The ...

ATLANTA — The trial involving rapper Young Thug and the alleged YSL street gang continues Tuesday following the long holiday weekend and a brief break in proceedings. Court was last in session ...

The first version of Recursion’s platform identified ... for the molecule and plans to talk to the FDA about an additional trial. Recursion is at the forefront of efforts to treat CCM, but ...

Hundreds of former rugby players are lining up to say head injuries have destroyed their lives. The players are accusing the sport’s governing bodies of failing to look after their welfare after ...

A French retiree went on trial Monday for allowing scores of strangers to rape his wife after he drugged her, in a case that has horrified the country. Fifty men, recruited online, are also being ...

In the book, Lily tells Ryle about her abusive father on the first night on the rooftop. However, in the movie version of It Ends With Us, Lily does not tell Ryle about her abusive father until after ...

Trump's lawyers are seeking to delay his election fraud trial in Washington, D.C. Donald Trump arrives for a town hall campaign event on August 29, 2024, in La Crosse, Wisconsin. Trump's lawyers ...

A man is accused of drugging his wife and then inviting dozens of men to rape her over almost a decade. The questions raised by the case have unsettled the country. By Catherine Porter and ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...